doi:10.3969/j.issn.1674-7445.2016.04.002

[1]

Weir MR, Burgess ED, Cooper JE, et al. Assessment and management of hypertension in transplant patients[J]. J Am Soc Nephrol,2015,26(6):1248-1260. doi: 10.1681/ASN.2014080834

[2]

James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8)[J]. JAMA,2014,311(5):507-520. doi: 10.1001/jama.2013.284427

[3]

Zanchetti A, Thomopoulos C, Parati G. Randomized controlled trials of blood pressure lowering in hypertension: a critical reappraisal[J]. Circ Res,2015,116(6):1058-1073. doi: 10.1161/CIRCRESAHA.116.303641

[4]

Fussner LA, Heimbach JK, Fan C, et al. Cardiovascular disease after liver transplantation: when, what, and who is at risk[J]. Liver Transpl,2015,21(7):889-896. doi: 10.1002/lt.24137

[5]

Mangray M, Vella JP. Hypertension after kidney transplant[J]. Am J Kidney Dis,2011,57(2):331-341. doi: 10.1053/j.ajkd.2010.10.048

[6]

Husain-Syed F, McCullough PA, Birk HW, et al. Cardio-pulmonary-renal interactions: a multidisciplinary approach[J]. J Am Coll Cardiol,2015,65(22):2433-2448. doi: 10.1016/j.jacc.2015.04.024

[7]

Kittleson MM, Kobashigawa JA. Long-term care of the heart transplant recipient[J]. Curr Opin Organ Transplant,2014,19(5):515-524. doi: 10.1097/MOT.0000000000000117

[8]

Weiner DE, Carpenter MA, Levey AS, et al. Kidney function and risk of cardiovascular disease and mortality in kidney transplant recipients: the FAVORIT trial[J]. Am J Transplant,2012,12(9):2437-2445. doi: 10.1111/ajt.2012.12.issue-9

[9]

Luca L, Westbrook R, Tsochatzis EA. Metabolic and cardiovascular complications in the liver transplant recipient[J]. Ann Gastroenterol,2015,28(2):183-192. http://cn.bing.com/academic/profile?id=2114204825&encoded=0&v=paper_preview&mkt=zh-cn

[10]

Savioli G, Surbone S, Giovi I, et al. Early development of metabolic syndrome in patients subjected to lung transplantation[J]. Clin Transplant,2013,27(3):E237-E243. http://cn.bing.com/academic/profile?id=1996779520&encoded=0&v=paper_preview&mkt=zh-cn

[11]

Mange KC, Cizman B, Joffe M, et al. Arterial hypertension and renal allograft survival[J]. JAMA,2000,283(5):633-638. doi: 10.1001/jama.283.5.633

[12]

Tedla FM, Brar A, Browne R, et al. Hypertension in chronic kidney disease: navigating the evidence[J]. Int J Hypertens,2011:132405. http://cn.bing.com/academic/profile?id=2080209849&encoded=0&v=paper_preview&mkt=zh-cn

[13]

Vecchiati A, Tellatin S, Angelini A, et al. Coronary microvasculopathy in heart transplantation: consequences and therapeutic implications[J]. World J Transplant,2014,4(2):93-101. http://cn.bing.com/academic/profile?id=1417202303&encoded=0&v=paper_preview&mkt=zh-cn

[14]

Carpenter MA, John A, Weir MR, et al. BP, cardiovascular disease, and death in the folic acid for vascular outcome reduction in transplantation trial[J]. J Am Soc Nephrol,2014,25(7):1554-1562. doi: 10.1681/ASN.2013040435

[15]

Kahwaji J, Bunnapradist S, Hsu JW, et al. Cause of death with graft function among renal transplant recipients in an integrated healthcare system[J]. Transplantation,2011,91(2):225-230. doi: 10.1097/TP.0b013e3181ff8754

[16]

Mayszko J, Mayszko J, Bachórzewska-Gajewska H, et al. Inadequate blood pressure control in most kidney transplant recipients and patients with coronary artery disease with and without complications[J]. Transplant Proc,2009,41(8):3069-3072. doi: 10.1016/j.transproceed.2009.07.078

[17]

Martínez-Saldivar B, Prieto J, Berenguer M, et al. Control of blood pressure in liver transplant recipients[J]. Transplantation,2012,93(10):1031-1037. doi: 10.1097/TP.0b013e31824cd5e6

[18]

Wasilewski G, Przybylowski P, Janik L, et al. Inadequate blood pressure control in orthotopic heart transplant: is there a role of kidney function and immunosuppressive regimen?[J]. Transplant Proc,2014,46(8):2830-2834. doi: 10.1016/j.transproceed.2014.09.034

[19]

中国高血压防治指南修订委员会. 中国高血压防治指南2010[J].中华心血管病杂志,2011,39(7):579-616.

Writing Group of 2010 Chinese Guidelines for the Management of Hypertension. 2010 Chinese guidelines for the management of hypertension[J]. Chin J Cardiol,2011,39(7):579-616.

[20]

Taler SJ, Agarwal R, Bakris GL, et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for management of blood pressure in CKD[J]. Am J Kidney Dis,2013,62(2):201-213. doi: 10.1053/j.ajkd.2013.03.018

[21]

Chatzikyrkou C, Menne J, Gwinner W, et al. Pathogenesis and management of hypertension after kidney transplantation[J]. J Hypertens,2011,29(12):2283-2294. doi: 10.1097/HJH.0b013e32834bd1e7

[22]

Fernandez Fresnedo G, Franco Esteve A, Gómez Huertas E, et al. Ambulatory blood pressure monitoring in kidney transplant patients: RETENAL study[J]. Transplant Proc,2012,44(9):2601-2602. doi: 10.1016/j.transproceed.2012.09.037

[23]

Ahmed J, Ozorio V, Farrant M, et al. Ambulatory vs office blood pressure monitoring in renal transplant recipients[J]. J Clin Hypertens, 2015,17(1):46-50. doi: 10.1111/jch.2015.17.issue-1

[24]

Wadei HM, Amer H, Taler SJ, et al. Diurnal blood pressure changes one year after kidney transplantation: relationship to allograft function, histology, and resistive index[J]. J Am Soc Nephrol,2007,18(5):1607-1615. doi: 10.1681/ASN.2006111289

[25]

Hermida RC, Ayala DE, Fernández JR, et al. Sleep-time blood pressure: prognostic value and relevance as a therapeutic target for cardiovascular risk reduction[J]. Chronobiol Int,2013,30(1/2):68-86. http://cn.bing.com/academic/profile?id=2088062541&encoded=0&v=paper_preview&mkt=zh-cn

[26]

Ramesh Prasad GV. Ambulatory blood pressure monitoring in solid organ transplantation[J]. Clin Transplant,2012,26(2):185-191. doi: 10.1111/ctr.2012.26.issue-2

[27]

Lakkis JI, Weir MR. Treatment-resistant hypertension in the transplant recipient[J]. Semin Nephrol,2014,34(5):560-570. doi: 10.1016/j.semnephrol.2014.08.010

[28]

Ambrosi P, Kreitmann B, Habib G. Home blood pressure monitoring in heart transplant recipients: comparison with ambulatory blood pressure monitoring[J]. Transplantation,2014,97(3):363-367. http://paper.medlive.cn/literature/1449982

[29]

Hoorn EJ, Walsh SB, McCormick JA, et al. The calcineurin inhibitor tacrolimus activates the renal sodium chloride cotransporter to cause hypertension[J]. Nat Med,2011,17(10):1304-1309. http://cn.bing.com/academic/profile?id=2167968191&encoded=0&v=paper_preview&mkt=zh-cn

[30]

Hesselink DA, Bouamar R, Elens L, et al. The role of pharmacogenetics in the disposition of and response to tacrolimus in solid organ transplantation[J]. Clin Pharmacokinet,2014, 53(2):123-139. doi: 10.1007/s40262-013-0120-3

[31]

Hricik DE. Metabolic syndrome in kidney transplantation: management of risk factors[J]. Clin J Am Soc Nephrol,2011,6(7):1781-1785. doi: 10.2215/CJN.01200211

[32]

Ghanta M, Kozicky M, Jim B. Pathophysiologic and treatment strategies for cardiovascular disease in end-stage renal disease and kidney transplantations[J]. Cardiol Rev,2015,23(3):109-118. http://cn.bing.com/academic/profile?id=2019324863&encoded=0&v=paper_preview&mkt=zh-cn

[33]

Hernandez Voth AR, Benavides Mañas PD, De Pablo Gafas A, et al. Sleep-related breathing disorders and lung transplantation[J]. Transplantation,2015,99(9):e127-e131. http://cn.bing.com/academic/profile?id=2321141292&encoded=0&v=paper_preview&mkt=zh-cn

[34]

Goicoechea M, Garcia de Vinuesa S, Verdalles U, et al. Allopurinol and progression of CKD and cardiovascular events: long-term follow-up of a randomized clinical trial[J]. Am J Kidney Dis,2015,65(4):543-549. doi: 10.1053/j.ajkd.2014.11.016

[35]

Kim ED, Famure O, Li Y, et al. Uric acid and the risk of graft failure in kidney transplant recipients: a reassessment[J]. Am J Transplant,2015,15(2):482-488. doi: 10.1111/ajt.v15.2

[36]

Gois PH, Souza ER. Pharmacotherapy for hyperuricemia in hypertensive patients[J]. Cochrane Database Syst Rev,2013,1:CD008652. http://cn.bing.com/academic/profile?id=1829757098&encoded=0&v=paper_preview&mkt=zh-cn

[37]

Sikma MA, van Maarseveen EM, van de Graaf EA, et al. Pharmacokinetics and toxicity of tacrolimus early after heart and lung transplantation[J]. Am J Transplant,2015,15(9):2301-2313. doi: 10.1111/ajt.v15.9

[38]

Fidalgo P, Ahmed M, Meyer SR, et al. Incidence and outcomes of acute kidney injury following orthotopic lung transplantation: a population-based cohort study[J]. Nephrol Dial Transplant,2014,29(9):1702-1709. doi: 10.1093/ndt/gfu226

[39]

Fioretto P, Najafian B, Sutherland DE, et al. Tacrolimus and cyclosporine nephrotoxicity in native kidneys of pancreas transplant recipients[J]. Clin J Am Soc Nephrol,2011,6(1):101-106. doi: 10.2215/CJN.03850510

[40]

Wlodarczyk Z, Glyda M, Ko s′ cianska L, et al. Prevalence of arterial hypertension following kidney transplantation: a multifactorial analysis[J]. Ann Transplant,2003,8(2):43-46. http://cn.bing.com/academic/profile?id=2418788576&encoded=0&v=paper_preview&mkt=zh-cn

[41]

Thomas B, Taber DJ, Srinivas TR. Hypertension after kidney transplantation: a pathophysiologic approach[J]. Curr Hypertens Rep,2013,15(5):458-469. doi: 10.1007/s11906-013-0381-0

[42]

Palanisamy A, Reeves-Daniel AM, Freedman BI. The impact of APOL1, CAV1, and ABCB1 gene variants on outcomes in kidney transplantation: donor and recipient effects[J]. Pediatr Nephrol,2014,29(9):1485-1492. doi: 10.1007/s00467-013-2531-7

[43]

Grinyo JM, Saval N, Campistol JM, et al. Clinical assessment and determinants of chronic allograft nephropathy in maintenance renal transplant patients[J]. Nephrol Dial Transplant,2011,26(11):3750-3755. doi: 10.1093/ndt/gfr091

[44]

Thomas B, Weir MR. The evaluation and therapeutic management of hypertension in the transplant patient[J]. Curr Cardiol Rep,2015,17(11):95. doi: 10.1007/s11886-015-0647-z

[45]

Wong W, Tolkoff-Rubin N, Delmonico FL, et al. Analysis of the cardiovascular risk profile in stable kidney transplant recipients after 50% cyclosporine reduction[J]. Clin Transplant,2004,18(4):341-348. doi: 10.1111/ctr.2004.18.issue-4

[46]

Johnson RW, Kreis H, Oberbauer R, et al. Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure[J]. Transplantation,2001,72(5):777-786. doi: 10.1097/00007890-200109150-00007

[47]

Diekmann F. Immunosuppressive minimization with mTOR inhibitors and belatacept[J]. Transpl Int,2015,28(8):921-927. doi: 10.1111/tri.2015.28.issue-8

[48]

Gullestad L, Mortensen SA, Eiskjr H, et al. Two-year outcomes in thoracic transplant recipients after conversion to everolimus with reduced calcineurin inhibitor within a multicenter, open-label, randomized trial[J]. Transplantation,2010,90(12):1581-1589. doi: 10.1097/TP.0b013e3181fd01b7

[49]

Knight SR, Morris PJ. Steroid avoidance or withdrawal after renal transplantation increases the risk of acute rejection but decreases cardiovascular risk. a Meta-analysis[J]. Transplantation,2010,89(1):1-14. doi: 10.1097/TP.0b013e3181c518cc

[50]

Philipp T, Martinez F, Geiger H, et al. Candesartan improves blood pressure control and reduces proteinuria in renal transplant recipients: results from SECRET[J]. Nephrol Dial Transplant,2010,25(3):967-976. doi: 10.1093/ndt/gfp581

[51]

Ibrahim HN, Jackson S, Connaire J, et al. Angiotensin Ⅱ blockade in kidney transplant recipients[J]. J Am Soc Nephrol,2013,24(2):320-327. doi: 10.1681/ASN.2012080777

[52]

Hiremath S, Fergusson D, Doucette S, et al. Renin angiotensin system blockade in kidney transplantation: a systematic review of the evidence[J]. Am J Transplant,2007,7(10):2350-2360. doi: 10.1111/ajt.2007.7.issue-10

[53]

Cross NB, Webster AC, Masson P, et al. Antihypertensive treatment for kidney transplant recipients[J]. Cochrane Database Syst Rev,2009(3):CD003598. http://cn.bing.com/academic/profile?id=1787835872&encoded=0&v=paper_preview&mkt=zh-cn

[54]

Heinze G, Mitterbauer C, Regele H, et al. Angiotensin-converting enzyme inhibitor or angiotensin Ⅱ type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation[J]. J Am Soc Nephrol,2006,17(3):889-899. doi: 10.1681/ASN.2005090955

[55]

Opelz G, Zeier M, Laux G, et al. No improvement of patient or graft survival in transplant recipients treated with angiotensin-converting enzyme inhibitors or angiotensin Ⅱ type 1 receptor blockers: a collaborative transplant study report[J]. J Am Soc Nephrol,2006,17(11):3257-3262. doi: 10.1681/ASN.2006050543

doi: 10.3969/j.issn.1674-7445.2016.04.002

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

doi: 10.3969/j.issn.1674-7445.2016.04.002

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Export File

Citation

Format

Content